Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy

NCT02979561 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

200

Enrollment

NETWORK

Sponsor class

Conditions

Angiographically Confirmed Acute Massive Pulmonary Embolism Treated With Endovascular Mechanical Fragmentation and Thrombolytic Therapy

Interventions

DRUG: Dabigatran Etexilate
DRUG: Warfarin

Sponsor

Meshalkin Research Institute of Pathology of Circulation